Objective To explore and analyze the effect of glucocorticoid combined with cyclophosphamide in the treatment of nephrotic syndrome. Methods: A total of 100 patients with nephrotic syndrome who were admitted to our hospital from February 2021 to February 2022 were randomly divided into a control group (glucocorticoid treatment, n=50 cases) and a research group (glucocorticoid combined with cyclophosphamide treatment, n=50 cases). The clinical effects of the two groups were compared, and the renal function indicators and inflammatory indicators of patients before and after treatment were measured. Results The overall curative rate of treatment group was 94.00％, which was higher than that of control group (P ＜ 0.05). The quantities of Scr, BUN and 24h urinary protein in the research group after treatment were (80.25±8.42) μ mol/L, (5.89±1.02) mmol/L and (1.04±0.52) g, respectively, which were lower than those in the control group (P ＜ 0.05). Besides, the levels of TNF-α and IL-6 in the study group after treatment were (1.93±0.83)ng/ml/mL and (24.04±2.15)pg/ml/mL, respectively, which were lower than those in the control group (P＜0.05). Conclusion: glucocorticoid combined with cyclophosphamide in the treatment of nephrotic syndrome has reliable effect. it can significantly improve renal function and reduce inflammatory reaction, worthy of promotion.
关键词
糖皮质激素/环磷酰胺/肾病综合征/肾功能/炎性指标
Key words
glucocorticoid/Cyclophosphamide/Nephrotic syndrome/renal function/Inflammatory indices
万方数据